Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Update on viral hepatitis: 2005.

Stephen N Wong1, Anna S F Lok

  • 1Division of Gastroenterology, University of Michigan Medical School, Ann Arbor, 48109, USA.

Current Opinion in Gastroenterology
|March 22, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Update on combination therapies against HBV in clinical investigations.

Antiviral research·2025
Same author

Recurrent Erythropoietic Protoporphyria Post Liver Transplant.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2025
Same author

Accurate prediction of HCC risk in patients with chronic HBV infection: HBeAg status and HBsAg level matter.

Hepatology (Baltimore, Md.)·2025
Same author

Safety and efficacy of a defined bacterial consortium, VE303, to treat HE.

Hepatology communications·2025
Same author

Reply: The exact predictive value of HBcrAg and HBV RNA in serological status and disease activity in CHB.

Hepatology (Baltimore, Md.)·2024
Same author

Cure can be achieved by conversion to microwave ablation following atezolizumab-bevacizumab therapy in unresectable hepatocellular carcinoma.

Journal of liver cancer·2024

New treatments for viral hepatitis show promise. Lamivudine helps chronic hepatitis B, while new drugs like entecavir and tenofovir combat resistance. Hepatitis C treatments are advancing for specific genotypes and advanced liver disease.

Area of Science:

  • Hepatology
  • Virology
  • Internal Medicine

Background:

  • Viral hepatitis remains a significant global health concern.
  • Advances in antiviral therapies are crucial for managing chronic infections.
  • Understanding treatment resistance is key to improving patient outcomes.

Purpose of the Study:

  • To summarize recent developments in viral hepatitis treatment and prevention.
  • To review publications from December 2004 to November 2005.
  • To highlight progress in managing hepatitis B and C.

Main Methods:

  • Literature review of publications within a specified timeframe.
  • Analysis of clinical trial data and therapeutic outcomes.
  • Synthesis of findings on antiviral resistance and treatment efficacy.

Related Experiment Videos

Main Results:

  • Lamivudine therapy reduced adverse outcomes in chronic hepatitis B, though resistance can diminish benefits.
  • Entecavir and tenofovir demonstrated efficacy against lamivudine-resistant hepatitis B.
  • Shorter peginterferon-ribavirin treatment was feasible for hepatitis C genotypes 2/3; retreatment improved response rates in relapsers.
  • Hepatitis C patients with advanced liver disease showed potential for sustained virological response but with higher complication rates.

Conclusions:

  • Antiviral resistance in chronic hepatitis B necessitates evolving treatment strategies.
  • Significant advances were made in hepatitis C treatment, including for specific genotypes and decompensated cirrhosis.
  • Ongoing research is vital for optimizing viral hepatitis management.